Personalis, Inc. (PSNL)

1,6500 +0,0850 (+5,43%) Börsenschluss: 04:00PM EDT

Personalis, Inc.

6600 Dumbarton Circle
Fremont, CA 94555
United States
650 752 1300
https://www.personalis.com

Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter: 223

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Christopher M. Hall	President, CEO & Director	963,75k	N/A	1969
Mr. Aaron L. Tachibana	CFO & COO	811k	N/A	1961
Mr. Stephen M. Moore J.D.	Senior VP, Chief Legal Officer & Corporate Secretary	597,98k	N/A	1972
Dr. Richard Chen M.D., M.S.	Executive VP of R&D and Chief Medical Officer	800,6k	N/A	1971
Dr. Russ B. Altman M.D., Ph.D.	Co-Founder and Member of Clinical & Scientific Advisory Board	N/A	N/A	N/A
Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D.	Co-Founder and Member of Clinical & Scientific Advisory Board	N/A	N/A	1971
Dr. Michael P. Snyder Ph.D.	Co-Founder and Member of Clinical & Scientific Advisory Board	N/A	N/A	N/A
Mr. Michael J Fitzpatrick	Vice President of Worldwide Sales	N/A	N/A	N/A
Dr. Christian Haudenschild Ph.D.	Senior Vice President of Genomic Laboratory Operations	N/A	N/A	N/A
Mr. Stephane Mouradian Ph.D.	Senior Vice President of Business Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

Corporate Governance

Personalis, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 6, Vorstand: 4, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.